Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 21, 2023, Rhythm Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders. A total of 49,290,096 shares of common stock were present online or represented by proxy at the meeting, representing approximately 86.7% percent of the Company's outstanding common stock as of the April 24, 2023 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2023.





Item 1 - Election of three Class III Directors to serve until the 2026 Annual
Meeting of Stockholders, and until their respective successors have been duly
elected and qualified.



         NOMINEE             Votes FOR    Votes WITHHELD   Broker Non-Votes
Camille L. Bedrosian, M.D.   43,804,864     2,854,511         2,630,721
    David W.J. McGirr        42,919,509     3,739,866         2,630,721
  David P. Meeker, M.D.      45,045,696     1,613,679         2,630,721

Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.





Votes FOR    Votes AGAINST   Votes ABSTAINED   Broker Non-Votes
49,239,432      22,310           28,354               0

Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.





Votes FOR    Votes AGAINST   Votes ABSTAINED   Broker Non-Votes
38,842,201     1,938,094        5,879,080         2,630,721

Based on the foregoing votes, Camille L. Bedrosian, M.D., David W.J. McGirr and David P. Meeker, M.D. were elected as Class III Directors, and Items 2 and 3 were approved.

© Edgar Online, source Glimpses